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ABSTRACT
U1-snRNA is an integral part of the U1 ribonucleo-
protein pivotal for pre-mRNA splicing. Toll-like
receptor (TLR) signaling has recently been asso-
ciated with immunoregulatory capacities of
U1-snRNA. Using lung A549 epithelial/carcinoma
cells, we report for the first time on interferon reg-
ulatory factor (IRF)-3 activation initiated by endoso-
mally delivered U1-snRNA. This was associated
with expression of the IRF3-inducible genes
interferon-b (IFN-b), CXCL10/IP-10 and indoleamine
2,3-dioxygenase. Mutational analysis of the
U1-snRNA-activated IFN-b promoter confirmed the
crucial role of the PRDIII element, previously proven
pivotal for promoter activation by IRF3. Notably,
expression of these parameters was suppressed
by bafilomycin A1, an inhibitor of endosomal acidifi-
cation, implicating endosomal TLR activation. Since
resiquimod, an agonist of TLR7/8, failed to stimulate
A549 cells, data suggest TLR3 to be of prime rele-
vance for cellular activation. To assess the overall
regulatory potential of U1-snRNA-activated epithe-
lial cells on cytokine production, co-cultivation with
peripheral blood mononuclear cells (PBMC) was
performed. Interestingly, A549 cells activated by
U1-snRNA reinforced phytohemagglutinin-induced
interleukin-10 release by PBMC but suppressed
that of tumor necrosis factor-a, indicating an anti-
inflammatory potential of U1-snRNA. Since U1-
snRNA is enriched in apoptotic bodies and epithelial
cells are capable of performing efferocytosis,
the present data in particular connect to
immunobiological aspects of apoptosis at host/
environment interfaces.
INTRODUCTION
With one million copies per nucleus U1-snRNA is the
most abundant small nuclear RNA (snRNA) in eukaryo-
tic cells. The highly conserved molecule is the deﬁning
component of the U1-ribonucleoprotein (RNP) that, by
recognizing the 50 splice site of precursor mRNA, plays
a vital role in the fundamental task of RNA processing
(1,2). The concept that U1 RNP, in particular U1-snRNA,
may in addition exhibit immunomodulatory properties
originates from observations that relate autoantibodies
targeting U1-RNP to secretion of type I interferons
(IFN) and the pathogenesis of systemic lupus erythemato-
sus (SLE) (3–6). Speciﬁcally, U1-snRNA has recently been
shown to induce release of type I IFN from plasmacytoid
dendritic cells (4–6) as well as interleukin (IL)-6 and IL-8
from endometrial cells (7).
In context of SLE, it has been suggested that extra-
nuclear U1-snRNA, in other words misplaced U1-
snRNA, delivers its activating/regulatory signals to
competent cells tharough endosomal uptake during pha-
gocytosis of U1-RNP-containing immune complexes (4,6).
A diﬀerent scenario that may apply to diverse pathophy-
siological conditions is based on the observation that U1
RNP enriches in apoptotic bodies (8–13). Accordingly, it
is reasonable to assume that uptake of apoptotic bodies
during eﬀerocytosis (14,15) likewise delivers U1-snRNA
to the signaling machinery located at the endosomal
compartment.
Composed of 164 nucleotides and characterized by
stretches of double-stranded RNA (1), U1-snRNA is
potentially detected by several sensors of innate immunity.
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nize double- and single-stranded RNA, respectively
(16–20). Those receptors have been previously associated
with cellular activation by misplaced U1-snRNA (4,5,7).
Endosomal delivery of U1-snRNP in fact mediates pro-
duction of IFN-a by human peripheral blood mononuc-
lear cells. Notably, pretreatment of U1-snRNP complexes
with RNase A, but not with proteinase, nulliﬁed IFN-a
release identifying U1-snRNA as the signaling principle
(4). In addition to endosomal TLRs, protein kinase R
(PKR) (17) as well as retinoic acid inducible gene-I
(RIG-I) and melanoma diﬀerentiation-associated gene-5
(MDA5) are activated by RNA. However, it is unlikely
that the latter two, both members of the family of RNA
helicases (17,21), are involved in sensing misplaced U1-
snRNA. Speciﬁcally, activation of RIG-I appears to be
mediated primarily by RNA molecules containing a
50-triphosphate moiety (22), which is uncommon to eukar-
yotic RNA, including U1-snRNA. Recent data moreover
indicate that activation of MDA5 demands extended
stretches of double-stranded RNA (23). Notably, these
are substantially longer than those found in U1-snRNA.
Epithelial cells are a vital component of the innate
immune system and determine course of diseases at
host/environment interfaces (24,25). Notably, epithelial
cells are also capable of executing the fundamental
program of eﬀerocytosis (14,15,26,27). Since current
knowledge on activation of epithelial cells by misplaced
U1-snRNA is merely fragmentary, we set out to system-
atically investigate eﬀects of endosomally-delivered
U1-snRNA on human A549 lung epithelial cells.
MATERIALS AND METHODS
Materials
Baﬁlomycin A1 (Baf), phytohemagglutinin (PHA) and
cycloheximide (CHX) were purchased from Sigma-
Aldrich (Taufkirchen, Germany). Recombinant ﬂagellin
(Flg, Salmonella muenchen), resiquimod/R-848 (Rq) and
lipopolysaccharide (LPS) (E. coli, serotype R515) were
from Alexis Biochemicals (Lausen, Switzerland).
Polyinosinic:polycytidylic acid [poly(I:C) or PIC] was pur-
chased from Amersham Biosciences/GE Healthcare
(Munich, Germany). Tumor necrosis factor-a (TNF-a)
was kindly provided by the Knoll AG (Ludwigshafen,
Germany). IL-1b was from Invitrogen/Biosource
(Karlsruhe, Germany).
Cultivation of A549 and DLD-1 cells
Human A549 lung epithelial/carcinoma cells were
obtained from the German Collection of Microorganisms
and Cell Cultures (Braunschweig, Germany). Cells were
maintained using RPMI 1640, supplemented with
100U/ml penicillin, 100mg/ml streptomycin, 10% heat-
inactivated FCS and 10mM HEPES buﬀer (GIBCO-
BRL, Eggenstein, Germany). This same culture medium
was used for experiments (except for cocultivation with
PBMC, see below). Human DLD-1 colon epithelial/carci-
noma cells were obtained from the Centre for Applied
Microbiology & Research (Salisbury, United Kingdom).
For maintenance and experiments, cells were cultured in
DMEM supplemented with 100U/ml penicillin, 100mg/ml
streptomycin and 10% heat-inactivated FCS (GIBCO-
BRL). For experiments, A549 or DLD-1 cells grown on
6-well polystyrene plates (Greiner, Frickenhausen,
Germany) were incubated using the aforementioned cul-
ture media at  80% conﬂuence. Cultivation of cells was
performed at 378C and 5% CO2.
Isolation of peripheral blood mononuclear cells (PBMC),
standard cultivation and co-cultivation with A549 cells
The study protocol and consent documents were approved
by the ‘Ethik Kommission’ of the University Hospital
Goethe-University Frankfurt. Informed consent was
obtained from volunteers. Healthy donors had abstained
from taking drugs for 2 weeks prior to the study. PBMC
were freshly isolated from peripheral blood using
Histopaque-1077 (Sigma-Aldrich) according to the man-
ufacturer’s instructions. For standard cultivation of
PBMC, cells were resuspended in RPMI 1640 supplemen-
ted with 10mM HEPES, 100U/ml penicillin, 100mg/ml
streptomycin and 1% human Serum (Invitrogen,
Karlsruhe, Germany) and seeded at 3 10
6 cells/ml in
round-bottom polypropylene tubes (Greiner).
For subsequent cocultivation with PBMC, A549 cells
at  80% conﬂuence cultured in 6-well polystyrene
plates (Costar, Bodenheim, Germany) were transfected
with U1-snRNA as described below. After the 4h trans-
fection procedure and medium change to PBMC coculture
medium (see below), 9 10
6 PBMC seeded into
Transwell-Clear inserts (0.4mm pore size, Costar) were
placed on top of the A549 cultures. Immediately before
cocultivation, PBMC had been resuspended in PBMC
coculture medium [RPMI 1640 supplemented with
10mM HEPES, 100U/ml penicillin, 100mg/ml streptomy-
cin and 3% heat-inactivated FCS (GIBCO-BRL)]. Co-
cultivation was performed for 72h in a total volume of
3ml of the aforementioned coculture medium.
Cloning and preparation of human U1- and U2-snRNA
by in vitro transcription
The human U1-snRNA gene (V00591, nt 394–557) was
cloned into the pCDNA3-vector (BglII, HindIII). A T7
promoter sequence was introduced directly in front of
the U1-snRNA gene. The following primers were used
for cloning purposes: forward, 50-TCAGATCTTAAT
ACGACTCACTATAGGGATACTTACCTGGCAGGG
G-30; reverse, 50-CTAAGCTTCAGGGGAAAGCGCGA
ACG-30. The identity of the cloned fragment was con-
ﬁrmed by sequencing. U1-snRNA was transcribed using
the MEGAscript T7 High Yield Transcription Kit
(Ambion; Austin, TX, USA) according to manufacturer’s
instructions. The DNA template was digested by DNase I
provided with the kit. In order to eliminate 50-triphosphate
moieties from in vitro transcribed U1-snRNA that may
artiﬁcially activate RIG-I (22), the molecule was treated
with shrimp alkaline phosphatase (SAP; Promega,
Mannheim, Germany). For that purpose, a protocol
proven to eﬀectively remove radiolabeled 50-phosphate
ends from in vitro transcribed U1-snRNA by at least
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1mg transcribed U1-snRNA was treated with 0.3U SAP
in presence of 4U RNase inhibitor (Applied Biosystems,
Darmstadt, Germany) at 378C for 1h. To inactivate SAP,
samples were incubated at 658C for 15min. Subsequently,
U1-snRNA was precipitated by phenol:chloroform
extraction and isopropanol and washed with 70% ethanol.
U1-snRNA was dissolved in nuclease- and pyrogen-free
water. Size and integrity of U1-snRNA was visualized by
gel electrophoresis and its concentration was determined
by ND-1000 spectrophotometer (NanoDrop, Wilmington,
DE, USA). For cloning, in vitro transcription, and prepa-
ration of U2-snRNA (NR_002716, nt 1–187) the same
methodology was used as for U1-snRNA (forward
primer, 50-TCAGATCTTAATACGACTCACTATAGG
GATCGCTTCTCGGCCTTTTG-30; reverse primer, 50-C
TAAGCTTGGTGCACCGTTCCTGGAGG-30). The
identity of the cloned U2-snRNA fragment was conﬁrmed
by sequencing. U1- and U2-snRNA preparations were
aliquoted and stored at  808C.
Stimulation with U1-, U2-snRNA, or poly(I:C) by
transfection
For stimulation by endosomal delivery (28,29) of U1-, U2-
snRNA (see Figure 9), or poly(I:C), A549 cells (or DLD-1
cells, see Figure 7) were transfected as described below by
using the cationic liposome lipofectamine-2000
(Invitrogen). To control for hypothetical RIG-I activation
by remnant uncleaved 50-triphosphate ends (22) within
SAP-treated U1/U2-snRNA preparations, an additional
‘U1/U2-snRNA control’ (U1/U2ctr) was performed.
This U1/U2ctr consists of in vitro transcribed U1/U2-
snRNA containing 50-triphosphate ends (no SAP treat-
ment) at a ﬁnal concentration of 3% (see above) of
the SAP-treated U1/U2-snRNA amount used for stimu-
lation of cells. U1/U2ctr thus controls for residual
50-triphosphate ends in the SAP-treated U1/U2-snRNA
preparation. For transfection, U1-snRNA, U1ctr, U2-
snRNA, U2ctr or poly(I:C) were pre-incubated with 4ml
lipofectamine-2000 per sample for 20min in order to allow
formation of nucleic acid/lipofectamine-2000 complexes.
For stimulation purposes, complexes were then added to
cells under serum-free conditions. Control cells were
exposed to lipofectamine-2000 in the absence of nucleic
acids (indicated as mock transfection). Unless otherwise
indicated, supernatants containing lipofectamine-2000
were removed after 4h. Thereafter, cells were washed
twice with PBS and 2ml of fresh culture medium (con-
taining FCS) was added. Incubation periods indicated
throughout the study are understood as being started
at the time of lipofectamine-2000 addition to cells. By
using
32P-labeled U1-snRNA (see below), the fraction
of U1-snRNA actually taken up by A549 cells during
this 4h transfection procedure was determined to be
65.7% 7.2%. We also like to point out that the
amount of U1-snRNA on average delivered into a single
cell by the current transfection protocol can be regarded as
roughly in range of the endogenous molecule. Based on
the molar mass of U1-snRNA and the presence of  10
6
molecules per cell (1) the amount of endogenous
U1-snRNA per cell can be estimated as  93fg. Based
on the transfection eﬃciency of the protocol described
above and the transfected cell numbers, we deduce the
transfected amount of U1-snRNA to be 86 fg per cell
(for transfection of 0.1mg/ml U1-snRNA).
In addition to immunoregulatory properties, TLR3/
IRF3-dependent signaling appears to be capable of
promoting apoptosis under certain conditions (30–32).
Twenty four hours after U1-snRNA transfection, negli-
gible cytotoxicity was evident compared to mock-
transfection in A549 cell cultures as detected by light
microscopy (Figure 1C, inset). Quantiﬁcation of cell
layer total protein content (determined as a measure of
cell detachment resulting from apoptotic cell death)
showed a slight tendency towards decrease in A549 cell
cultures exposed to U1-snRNA for 24h [89.2% 11.1%
total protein for exposure to U1-snRNA (0.1mg/ml) com-
pared to mock-transfected control set as 100%, n=9].
A549 cell viability as detected by the WST-1 assay
(Roche Diagnostics, Mannheim, Germany) showed a sim-
ilar tendency after a 24h exposure to U1-snRNA
at 0.1mg/ml (84.4% 15.6% viability for exposure
to U1-snRNA compared to mock-transfected control
set as 100%, n=9). This tendency to slightly reduced via-
bility resulting from extended activation by U1-snRNA
did not reach statistical signiﬁcance in both assays
performed (analyzed by unpaired Student’s t-test on
raw data).
Analysis of in vitro transcribed and transfected
U1-snRNA integrity
U1-snRNA was synthesized in-vitro using T7 RNA poly-
merase (as described above) in the presence of [g-
32P]UTP
(800Ci/mmol; Perkin Elmer, Rodgau, Germany). After
SAP-treatment, A549 cells were transfected (as described
above) with
32P-labeled U1-snRNA. In order to proof
integrity of U1-snRNA, 1000 cpm of in-vitro transcribed
U1-snRNA (not transfected into cells) and 1000 cpm of
total cellular RNA isolated from U1-snRNA transfected
cells (after 4h) were separated on a 5% polyacrylamide/
8M urea gel and analyzed by PhosphoImager
(Fuji, Straubenhardt, Germany). One thousand cpm of a
32P-labeled glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) probe (184nt) served as size-control (U1-
snRNA: 164nt).
Digestion of U1-snRNA by benzonase and RNases A
and T1
U1-snRNA was exposed to benzonase (Novagen/Merck
Chemicals, Nottingham, UK) or DNase-free RNases
A/T1 (Roche Diagnostics) before transfection into cells.
The used benzonase is a genetically engineered Serratia
marcescens endonuclease digesting both, single- and
double-stranded RNA. According to the manufacturer’s
instructions, 0.1mg U1-snRNA was incubated with 25U
benzonase at 378C for 1h. For digestion of U1-snRNA by
RNases, the molecule was heated to 958C for 5min fol-
lowed by addition of RNase A/T1 and digestion at 308C
for 1h. The quality of U1-snRNA digestion was veriﬁed
by gel electrophoresis.
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Total RNA was isolated using TRI-Reagent (Sigma-
Aldrich) according to the manufacturer’s instructions. As
IFN-b mRNA only consists of one single exon, it was
impossible to design exon-spanning primers that exclude
ampliﬁcation of potentially contaminating genomic DNA.
Therefore, all RNA isolates were ﬁrst digested with
RNase-free DNase I (Roche Diagnostics) according to
the manufacturer’s instructions. After precipitation with
acid phenol and isopropanol and a wash with 70% etha-
nol, 1mg of total RNA was transcribed using random hex-
americ primers and Moloney virus reverse transcriptase
(RT; Applied Biosystems) according to the manufacturer’s
instructions. The following sequences were performed for
PCR: 948C for 10min (1 cycle); 948C for 1min, 608C
[GAPDH, interferon (IFN)-b, PKR, toll-like receptor
(TLR)-7, TLR8, RIG-I], 598C (TLR5), 588C [indoleamine
2,3-dioxygenase (IDO), CXCL10/IP-10], 568C (TLR4),
558C (MDA-5) or 478C (TLR3) for 1min and 728C for
1min (with the indicated numbers of cycles); ﬁnal exten-
sion phase at 728C for 7min. Primer sequences and length
of resulting amplicons: GAPDH (F): 50-ACCACAGTC
CATGCCATCAC-30, GAPDH (R): 50-TCCACCACCC
TGTTGCTGTA-30, 452bp, 24 cycles; IDO (F): 50-GAT
CCTAATAAGCCCCTGACT-30, IDO (R): 50-CAGCAT
GTCCTCCACCAG-30, 454bp, 31–33 cycles; IFN-b (F):
50-AGCTGCAGCAGTTCCAGAAG-30, IFN-b (R): 50-A
GTCTCATTCCAGCCAGTGC-30, 110bp, 30–32 cycles;
IP-10 (F): 50-GCATTCAAGGAGTACCTCT-30, IP-10
(R): 50-CCTTGCTAACTGCTTTCAG-30, 222bp, 30–33
cycles; PKR (F): 50-GCCCAGAACAGATTTCTTCG-30,
PKR (R): 50-TATCTGAGATGATGCCGTCCC-30,
150bp, 39 cycles; TLR3 (F): 50-GTCATCCAACAGAA
TCAT-30, TLR3 (R): 50-GATTAAATTCTTCTGCTT-30,
466bp, 39 cycles; TLR4 (F): 50-ATGGAGCTGAATTTC
TACAAAATCC-30, TLR4 (R): 50-GCTTCTGTAAACT
TGATAGTCC-30, 271bp, 35 cycles; TLR5 (F): 50-CTA
GAAGTCCCTTCTGCTAGGAC-30, TLR5 (R): 50-AA
GGGGAAGGATGAAGCAGTG-30, 236bp, 35 cycles;
TLR7 (F): 50-GGATGGAAACCAGCTACTAGAG-30,
TLR7 (R): 50-TAGGGACGGCGTGACATTG-30,
260bp, 39 cycles; TLR8 (F): 50-CAGAATAGCAG GCG
TAACACATCA-30, TLR8 (R): 50-ATGTCACAGGTGC
ATTCAAAGGG-30, 625bp, 39 cycles; RIG-I (F):
50-GAGCA GCAGGATTCGAAGAGA-30, RIG-I (R):
50-TTGCTCTTCCTCTGCCTCTG-30, 477bp, 39 cycles;
MDA5 (F): 50-CAGAAACCGGATTGCTGCT-30,
MDA5 (R): 50-GTGTCTGATTCTGAAACTACA-30,
335bp, 39 cycles. Identity of amplicons was conﬁrmed
by sequencing (310 Genetic Analyzer, Applied Biosys-
tems). Note the white banding pattern seen on agarose
gels (Figures 1AB, 2AB, 3C, 4AE and 7B) is due to the
loading dye.
Analysis of IL-18 binding protein (IL-18BP) mRNA by
quantative realtime PCR
During realtime PCR, changes in ﬂuorescence were caused
by the Taq-polymerase degrading the probe that contains
a ﬂuorescent dye (FAM used for IL-18BP, VIC for
GAPDH) and a quencher (TAMRA). Primers and
probe for IL-18BPa were designed using Primer Express
(Applied Biosystems) according to AF110798: forward,
50-ACCTCCCAGGCCGACTG-30; reverse, 50-CCTTGC
ACAGCTGCGTACC-30; probe, 50-CACCAGCCGGGA
ACGTGGGA-30. Ampliﬁcation of contaminating geno-
mic DNA was avoided by selecting an amplicon that
crosses an exon/intron boundary. For GAPDH
(4310884E), pre-developed assay reagents were used
(Applied Biosystems). Quantitative realtime PCR of
cDNA was performed on 7500 FAST Realtime PCR
System (Applied Biosystems): One initial step at 958C
for 20s was followed by 40 cycles at 958C for 3s and
608C for 30s. Detection, calculation of threshold cycles
(Ct values), and data analysis was performed by
Sequence Detector software. mRNA was quantiﬁed by
use of cloned cDNA standards for IL-18BP and
GAPDH, respectively. IL-18BP mRNA expression was
normalized to that of GAPDH.
Detection of phosphorylated interferon regulatory factor
(pIRF)-3, phosphorylated signal transducer and activator
of transcription (pSTAT)-1, pSTAT3, phosphorylated
eukaryotic initiation factor 2 (p-eIF2)-a, IRF7, p65
and IDO by immunoblot analysis
Total lysates with intracellular proteins were obtained by
treatment of cells with lysis buﬀer (150mM NaCl, 1mM
CaCl2, 25mM Tris–Cl, pH 7.4) containing 1% Triton-X-
100, protease inhibitor cocktail (Roche), DTT, Na3VO4,
PMSF (each 1mM), and NaF (20mM). Where indicated
(see Figure 6D), nuclear lysates were isolated as previously
described (33) and used to detect nuclear p65, IRF7 and
pIRF3. Proteins were separated on 10% SDS–PAGE gels
and transferred onto a Hybond-C Extramembrane (GE
Healthcare, Freiburg, Germany). pSTAT1 and pIRF3
were detected by primary rabbit polyclonal antibodies
whereas p-eIF2a and pSTAT3 were detected by primary
rabbit monoclonal antibodies (Cell Signaling, Frankfurt,
Germany). IDO and IRF7 were detected by primary
mouse monoclonal antibodies purchased from Millipore
(Schwalbach, Germany) and Santa Cruz Biotechnology
Inc. (Heidelberg, Germany), respectively. p65 was
detected using a goat polyclonal antibody obtained from
Santa Cruz Biotechnology Inc. Detection was achieved
by horseradish peroxidase-labeled secondary antibodies
(Bio-Rad, Munich, Germany), and a chemoluminescence
detection kit (GE Healthcare) according to manufac-
turer’s instructions.
For determination of transcription factor activation
(pSTAT1, pSTAT3, pIRF3, p65, IRF7), cells were stimu-
lated with U1-snRNA as described above. However, in
that case, nucleic acid/lipofectamine-2000 complexes
were not removed after four hours. Instead, protein lysates
were generated for up to 6h after onset of transfection for
time-course analyses.
Detection of TLR3 by immunofluorescence
A549 cells were seeded on cover slips in 24-well plates.
For analysis, cells were washed twice with PBS and Exed
in ice-cold methanol for 20min. After two washes with
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Triton-X-100/1% BSA (Sigma-Aldrich) in PBS for 30min
at room temperature. Primary and the secondary antibo-
dies were diluted in this buﬀer. For staining, cells were
incubated with a murine monoclonal anti-human TLR3
(BioLegend, San Diego, CA, USA) antibody for 1h at
room temperature. After two washes with PBS, cells
were incubated with an anti-mouse secondary antibody
(Cy3, Sigma-Aldrich) for 30min at room temperature in
the dark. After two additional PBS washes nuclei were
stained with DAPI and washed thrice with PBS. Finally,
samples were covered with ﬂuoromount (Biozol, Eching,
Germany) and analyzed using a confocal ﬂuorescence
microscope (LSM 510 Meta, Zeiss, Jena, Germany).
Luciferase reporter assays
An IFN-b promoter fragment was cloned into pGL3-Basic
(Promega, Mannheim, Germany) and entitled pGL3-
IFNb. Position of cloned DNA: nt  1t on t 282
(282nt). The following primers were used: (F): 50-GACT
CGAGAATTCTCAGGTCGTTTGC-30, (R): 50-GAAAG
CTTCCTTTCTCCATGGGTATG-30. In order to blunt
the pIRF3 binding site (PRDIII region) in the IFN-b pro-
moter (34), site directed mutagenesis was performed using
the QuikChange site-directed mutagenesis kit (Stratagene,
Amsterdam, Netherlands). The following primer was used:
pGL3-mutIFNb:5 0-ATGTAAATGACATAGGATTTCT
GAAAGGGAGAAGT-30. Identity of mutants was con-
ﬁrmed by sequencing. For each reaction conducted in
6-well plates 0.25 or 1mg (as indicated) of the respective
plasmids was transfected into A549 cells using lipofecta-
mine-2000
TM (Invitrogen) according to manufacturer’s
instructions. As a control for transfection eﬃciency 0.1mg
pRL-TK (Promega) coding for Renilla luciferase was
cotransfected. After 4h of transfection, culture medium
was changed and cells were rested for 20h. Thereafter,
cells were transfected with U1-snRNA as described
above. After a further 24h stimulation period, A549 cells
wereharvestedandluciferaseactivitywasdeterminedusing
the dual reporter gene system (Promega) and an automated
chemoluminescence detector (Berthold, Bad Wildbad,
Germany) according to manufacturers’ instructions. For
analysis, luciferase activity was normalized to that of
Renilla-TK. For data analyses, unstimulated control of
the same transfected plasmid was set as 1.
Detection of IFN-c, IL-10, CXCL10/IP-10, TNF-a and
IFN-b by enzyme linked immunosorbent assay (ELISA)
Concentrations of IFN-g, TNF-a, IP-10/CXCL10 (Phar-
mingen/BD Biosciences, Heidelberg, Germany), IL-10
(Diaclone/Ho ¨ lzl Diagnostics, Cologne, Germany), IFN-b
(PBL InterferonSource/R&D Systems, Wiesbaden Ger-
many) in cell-free cell culture supernatants were deter-
mined by ELISA according to the manufacturers’
instructions.
Statistics
Data are shown as mean SD (for A549 cells and
for DLD-1) or as mean SEM (for PBMC). Data are
presented as pg/ml, or fold-induction. If not stated
otherwise, raw data (A549 cells, DLD-1 cells and
PBMC) were analyzed by one-way ANOVA with post-
hoc Bonferroni correction (GraphPad 4.0).
RESULTS
IFN-b, IDO and IP-10 gene expression and activation
of IRF3 by misplaced U1-snRNA
Activation of innate immunity by RNA converges at
initiation of IRF3/5/7 signaling, a process that is supposed
to be accomplished mainly by action of RIG-I-like recep-
tors and by endosomal TLRs, speciﬁcally TLR3, TLR7
and TLR8 (16–21). In order to characterize activation of
A549 cells by misplaced U1-snRNA, endosomal delivery
was achieved by transfection (28,29). Thereafter, expres-
sion of prototypic IRF3-dependent genes was determined,
namely IFN-b, IDO and IP-10 (35–38). As shown in
Figure 1, mRNA expression of all three genes was induced
by U1-snRNA in dose- (A) and time-dependent (B)
manner. mRNA induction translated into secretion of
IFN-b (C) and IP-10 (D) as well as expression of cellular
IDO protein (E). Notably, U1ctr (see ‘Materials and
Methods’ section) was unable to mediate signiﬁcant induc-
tion of any of these three parameters (Figure 1BCD) indi-
cating that residual RIG-I activating 50triphosphates
hypothetically present in in vitro-transcribed and SAP-
treated U1-snRNA preparations are neglectable in this
experimental setup. As expected, induction of these
genes was paralleled by robust phosphorylation/activation
of IRF3 which was obviously absent in the U1ctr stimu-
latory control (Figure 1F). Sensing of U1-snRNA might
also result in activation of IRF3-related IRF7, targeting
the same ISRE DNA element, alike all IRFs (17,18,20).
However, IRF7 activation by exposure of A549 cells to
U1-snRNA (6h) was barely, if at all, detectable and thus
must be regarded as of minor relevance for direct action of
U1-snRNA compared to the strong, robust, and fast acti-
vation of IRF3 in these same experiments (data not
shown). IRF5 is another IRF family member also capable
of inducing IFN-b after its activation by the RNA sensors
RIG-I or TLR7/8. Characteristically, IRF5 is not acti-
vated by TLR3 (20,39). Since RIG-I and TLR7/8 are
unlikely to mediate activation of A549 cells by misplaced
U1-snRNA (see below), a role for IRF5 in this context can
be excluded.
In order to prove that intact U1-snRNA is actually
responsible for activation of A549 cells under those con-
ditions, RNA was degraded by pre-incubation with
RNase A/T1 (Figure 2AC) or benzonase (Figure 2BD).
Figure 2 demonstrates that RNA degradation nulliﬁed
U1-snRNA stimulatory activity detected by IDO and
IFN-b mRNA expression (AB) and phosphorylation of
IRF3 (CD). Notably, activation of A549 cells by U1-
snRNA was absent in cells exposed to U1-snRNA without
transfection as detected by IRF3 phosphorylation
(Figure 2E) and induction of IDO and IFNb (data not
shown). Integrity of transfected radiolabeled U1-snRNA
was analyzed by gel electrophoresis. Figure 2F demon-
strates that no signiﬁcant degradation of U1-snRNA
was detectable 4h after its transfection into A549 cells.
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U1-snRNA is suppressed by pre-incubation with bafilomycin
A1, is not mediated by PKR, and cannot be mimicked by
the TLR7/8 ligand resiquimod/R-848
In order to gain insight into the RNA sensing machinery
potentially available in A549 cells, PCR analysis was
performed and proved mRNA expression of TLR3,
TLR7, TLR8, PKR, RIG-I and MDA5 in this cell type.
In addition, mRNA expression of TLR4 and TLR5 is
shown (Figure 3A). Consequently, we sought to assess
the contribution of these sensors concerning cellular
activation by U1-snRNA. As already alluded to, MDA5
is supposed to be activated by extended stretches of
double-stranded RNA (23) and thus appears unlikely to
contribute to U1-snRNA immunoregulatory activity.
Baﬁlomycin A1 is a highly speciﬁc pharmacological
inhibitor of the vacuolar-type H
+-ATPase thereby
potently blocking endosomal acidiﬁcation and subsequent
endosomal TLR signaling. Accordingly, this compound
has been successfully employed to identify activation
of endosomal TLR signaling (40–43). As shown in
Figure 3B, pre-incubation with baﬁlomycin A1 entirely
prevented U1-snRNA-induced activation of IRF3. In con-
trast, phosphorylation of IRF3 was not inﬂuenced
by blockage of translation using cycloheximide, which is
Figure 1. IFN-b, IDO, and IP-10 gene expression and activation of IRF3 by misplaced U1-snRNA. (A) A549 cells were either kept as mock-transfected
control or were stimulated with the indicated concentrations of U1-snRNA for 8h. Alternatively, cells were stimulated with U1-snRNA at 0.1mg/ml or
U1ctr (0.003mg/ml) for the indicated time periods (B). Thereafter, cells were harvested and IP-10, IDO and IFN-b mRNA was assessed by RT-PCR
analysis. (A and B) One representative of three independently performed experiments for each experimental setup is shown. (C and D) A549 cells were
either kept as mock-transfected control or stimulated with U1-snRNA (0.1mg/ml) or U1ctr (0.003mg/ml) for 12h. Thereafter, IFN-b (C) and IP-10
(D) secretion was detected by ELISA analysis. IFN-b (n=3) and IP-10 (n=4) levels are expressed as means SD;
  P<0.01 compared to mock-
transfected control,
##P<0.01 compared to U1-snRNA stimulation. Figure 1C inset: light microscopy revealed neglectable cytotoxicity under the
inﬂuence of transfected U1-snRNA (0.1mg/ml, 24h) as compared to mock-transfection. (E) A549 cells were either kept as mock-transfected control or
stimulated with U1-snRNA (0.1mg/ml) for the indicated time periods. Thereafter, IDO protein expression was determined by immunoblot analysis.
One representative of three independently performed experiments is shown. (F) A549 cells were either kept as mock-transfected control or were
stimulated with either U1-snRNA (0.1mg/ml) or U1ctr (0.003mg/ml) for the indicated time periods. Thereafter, cellular pIRF3 content was determined
by immunoblot analysis. One representative of three independently performed experiments is shown.
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function. Impaired IRF3 signaling was associated with
striking reduction of IDO, IFN-b and IP-10 mRNA
expression (Figure 3C) and potent suppression of IFN-b
(Figure 3D) and IP-10 (Figure 3E) secretion. These data
indicate that endosomal TLR signaling likely plays a
key role for cellular activation under the inﬂuence of
misplaced U1-snRNA. In a further attempt to character-
ize mechanisms driving stimulatory properties of
U1-snRNA, expression of IDO and IFN-b mRNA was
investigated in response to TLR7/8 activation. For that
purpose A549 cells were treated with U1-snRNA or resi-
quimod/R-848, a membrane permeable agent activating
TLR7/TLR8 (44), as well as LPS (activating TLR4) and
ﬂagellin (activating TLR5) by using the standard protocol
for transfection of U1-snRNA. As shown in Figure 4A,
neither LPS nor ﬂagellin nor resiquimod were able to
mediate expression of IDO and IFN-b under those exper-
imental conditions. Analogous data were obtained with
regard to activation of IRF3 (Figure 4B). In contrast to
U1-snRNA, R-848 is membrane permeable and thus sup-
posed to reach TLR7/8 in the endosomal compartment
Figure 2. Biological activity of U1-snRNA is blunted by digestion using RNases A/T1 or benzonase and is dependent on U1-snRNA transfection.
U1-snRNA was digested by RNases A/T1 (A and C) or benzonase (B and D) as outlined in the ‘Materials and Methods’ section. A549 cells were
either kept as mock-transfected control or stimulated with intact or digested U1-snRNA (each at 0.1mg/ml). (A and B) After 24h, cells were
harvested and mRNA coding for IDO and IFN-b was determined by RT-PCR. For each experimental setup, one representative of ﬁve independently
performed experiments is shown. (C and D) After 6h, cells were harvested and cellular pIRF3 content was determined by immunoblot analysis. For
each experimental setup, one representative of three independently performed experiments is shown. (E) A549 cells were kept as unstimulated control
or exposed to U1-snRNA (0.1mg/ml) without transfection. In addition, cells were either kept as mock-transfected control or stimulated by standard
transfection with U1-snRNA (0.1mg/ml). After 2h, cells were harvested and cellular pIRF3 content was determined by immunoblot analysis. For
each experimental setup, one representative of three independently performed experiments is shown. (F)
32P-labeled U1-snRNA (0.1mg/ml) was
transfected by standard protocol into A549 cells. After 4h, total cellular RNA was isolated. Thereafter, integrity of transfected U1-snRNA was
assessed by gel electrophoresis and subsequent analysis using a PhosphoImager. Left lane (ivt), 1000 cpm of in vitro transcribed
32P-labeled
U1-snRNA (not transfected into cells); middle lane, 1000cpm of total RNA isolated 4h after transfection of
32P-labeled U1-snRNA into A549
cells; right lane
32P-labeled GAPDH probe (184nt) serving as size-control (U1-snRNA: 164nt).
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alike U1-snRNA, R-848 failed to mediate IRF3 activation
as well as IDO and IFN-b expression when exposed to
cells directly without transfection (data not shown).
R-848 was however active on human PBMC that were
stimulated with the compound as positive control for its
biological activity. In fact, we conﬁrmed previous data
(45) on robust activation of PBMC by R-848 (10mM) as
detected by IFNg secretion (63.5 42.1pg/ml for unsti-
mulated control versus 16 520 2848pg/ml for R-848 acti-
vation of PBMC, 24h incubation, n=3,p<0.01 analyzed
by unpaired Student’s t-test on raw data). These results
argue against a function of endosomal TLR7/8 yet sub-
stantiating a key role of TLR3 recognizing double-
stranded RNA for activation of A549 cells by misplaced
U1-snRNA. As a further negative control, cells were
transfected with total human RNA (derived from A549
cells). As shown in Figure 4AB, transfection of total
RNA was unable to activate A549 cells as detected by
IDO or IFN-b mRNA expression and IRF3 phosphoryla-
tion, respectively. These data agree with a recent report
indicating that human total RNA preparations are unable
to mediate endosomal TLR activation, speciﬁcally con-
cerning the RNA sensors TLR3 and TLR7/8 (46).
Since data presented herein supported involvement of
TLR3 in activation of A549 cells by misplaced U1-
snRNA, immunoﬂuorescence analysis visualizing TLR3
in A549 cells was performed (Figure 4C). In accord with
previous data (47), confocal microscopy revealed that
TLR3 primarily displays intracellular location with an
obvious granular staining pattern that furthermore con-
ﬁrms its vesicular occurrence. Notably, staining of TLR3
at the membrane was not detected and agrees with the
observation that exposure to U1-snRNA without lipo-
some-aided endosomal delivery failed to activate IRF3
(Figure 2E) as well as IDO and IFN-b expression (data
not shown) in A549 cells.
To assess the role of PKR in U1-snRNA-induced acti-
vation of A549 cells, stimulation of this kinase was veriﬁed
by analysis of eIF2a phosphorylation, a well-known
PKR primary substrate (17). Interestingly, activation of
A549 cells by misplaced U1-snRNA did not result in
Figure 3. Activation of A549 cells under the inﬂuence of U1-snRNA is inhibited by baﬁlomycin A1. (A) Mock-transfected A549 cells were analyzed
for expression of TLR3, TLR4, TLR5, TLR7, TLR8, RIG-I, MDA5 and PKR by RT–PCR. (B) A549 cells were either kept as mock-transfected
control or stimulated with U1-snRNA (0.1mg/ml). Where indicated, cells were pre-incubated (0.5h) with either baﬁlomycin A1 (Baf, 1mM) or CHX
(10mg/ml). All cultures were adjusted to a ﬁnal concentration of 0.1% DMSO (vehicle for Baf and CHX) throughout the experiment. After an
incubation period of 4h (total experiment: 4.5h) cellular expression of pIRF3 was analyzed by immunoblot analysis. One representative of three
independently performed experiments is shown. (C–E) A549 cells were either kept as mock-transfected control or stimulated with U1-snRNA
(0.1mg/ml). In Figure 3C, cells were also exposed to U1ctr (0.003mg/ml). Where indicated, cells were pre-incubated (0.5h) with baﬁlomycin
A1at 1mM. All cultures were adjusted to a ﬁnal concentration of 0.1% DMSO (vehicle for Baf) throughout the experiment. After removal of
liposomes (at 4h, see ‘Materials and Methods’ section) fresh baﬁlomycin A1 was added where indicated. (C) After an incubation period of 12h (total
experiment: 12.5h), cellular mRNA expression of IDO, IFN-b, and IP-10 was determined by RT-PCR. One representative of ﬁve independently
performed experiments is shown. (DE) After 12h, also secretion of IFN-b and IP-10 was determined by ELISA analysis. IFN-b (n=3) and IP-10
(n=4) levels are expressed as means SD;
  P<0.01 compared to mock-transfected control.
##P<0.01 compared to U1-snRNA stimulation.
8 Nucleic Acids Research, 2009phosphorylation of eIF2a (Figure 4D). As a positive con-
trol, cells were exposed to poly(I:C) (PIC). Poly(I:C) is
supposed to activate both, PKR (17) and TLR3 (17,19).
As expected, transfection of poly(I:C) not only stimulated
PKR, as detected by eIF2a phosphorylation, but more-
over induced activation of IRF3 as well as expression of
IDO and IFN-b mRNA (Figure 4E). These data indicate
that PKR is unlikely to be involved in activation of A549
cells under the inﬂuence of U1-snRNA.
Induction of IFN-b by U1-snRNA is dependent on the
ISRE-like PRDIII IFN-b promoter element
In order to substantiate that misplaced U1-snRNA is in
fact able to mediate gene expression by activating the IRF
pathway, IFN-b promoter analysis was performed. As
shown in Figure 5 and in accordance with aforementioned
data on IFN-b mRNA expression and protein secretion,
misplaced U1-snRNA upregulated IFN-b promoter activ-
ity which was suppressed by pre-incubation of cells with
baﬁlomycin A1 (A). Notably, mutation of the PRDIII
element, an ISRE-like site previously shown as crucial
for induction by IRF3 (34), suppressed activation of the
IFN-b promoter by U1-snRNA (Figure 5B). These results
demonstrate that misplaced U1-snRNA mediates IFN-b
production by action on the PRDIII promoter element,
most likely via IRF3.
Induction of STAT signaling under the influence of
misplaced U1-snRNA
In order to assess activation of the STAT-signaling path-
way by U1-snRNA in A549 cells, immunoblot analysis
of phosphorylated STAT molecules was performed.
Figure 4. Activation by U1-snRNA is unlikely mediated by TLR4, TLR5, TLR7/8 and PKR. (A and B) A549 cells were either kept as mock-
transfected control or were stimulated with U1-snRNA (0.1mg/ml). Where indicated, cells were stimulated with LPS (10mg/ml), ﬂagellin (Flg)
(100ng/ml), resiquimod (Rq) (10mg/ml), or total eukaryotic RNA (0.1mg/ml) by using the U1-snRNA transfection protocol. After 24h (A) and
4h(B), expression of IDO and IFN-b mRNA was analyzed by RT-PCR (A) and cellular pIRF3 content was determined by immunoblot analysis (B),
respectively. For each experimental setup, one representative of three independently performed experiments is shown. (C) TLR3 expression by mock-
transfected A549 cells was analyzed immunohistochemically using confocal microscopy (TLR3/Cy3; nuclei/DAPI). Insets, negative controls where
immunohistochemistry was performed in the absence of the primary antibody. (DE) A549 cells were either kept as mock-transfected control or
stimulated by transfection with U1-snRNA (0.1mg/ml), U1ctr (0.003mg/ml), or poly(I:C) (0.1mg/ml). (D) After 4h, cellular content of pIRF3 and
p-eIF2a was determined by immunoblot analysis. For that purpose the blot was cut in half. (E) After 24h, expression of IDO and IFN-b mRNA was
analyzed by RT-PCR. (D and E) One representative of three independently performed experiments is shown for each experimental setup.
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ing was engaged by misplaced U1-snRNA. Interestingly,
compared to IRF3, activation of both parameters was
delayed by at least 1h. Recently, we could demonstrate
that activation of STAT1 holds a pivotal position con-
cerning induction of the prototypic IFN-g-inducible gene
IL-18BP (48,49). Accordingly, misplaced U1-snRNA
mediated signiﬁcant upregulation of IL-18BP indicative
of enhanced biological activity of STAT1 under those
cconditions (Figure 6C). In contrast to STAT1, activa-
tion of nuclear factor-kB (NF-kB), as detected by p65
translocation to the nucleus, was not obvious after 2h of
exposure to U1-snRNA. As expected, p65 translocation
was achieved by the combination of IL-1b and TNFa
serving as positive control for NF-kB and negative control
for IRF3 dependent signaling. Those data also demon-
strate translocation of pIRF3 to the nuclear compartment
under the inﬂuence of U1-snRNA (Figure 6D).
Activation of DLD-1 colon epithelial/carcinoma cells by
misplaced U1-snRNA
In order to demonstrate that activation by misplaced U1-
snRNA can be observed in diﬀerent cell types, key ﬁnd-
ings detected in A549 cells were veriﬁed in DLD-1 cells. As
shown in Figure 7, misplaced U1-snRNA in fact was able
to mediate activation of IRF3 (A), which was associated
with expression of IDO (BC), IFN-b (B), and IP-10 (DE).
In accord with data on A549 cells, U1-snRNA eﬀects, as
detected by IRF3 activation and IP-10 release, were
potently suppressed in the presence of baﬁlomycin A1
(Figure 7AE) or after pre-treatment with benzonase
(Figure 7D).
Misplaced U1-snRNA mediates anti-inflammatory effects
as detected in A549 cell/PBMC co-culture experiments
In order to assess the overall regulatory potential of U1-
snRNA-activated A549 cells on inﬂammatory cytokine
production, co-cultivation with freshly isolated human
PBMC was performed in presence and absence of PHA.
Notably, pre-activation of A549 cells by U1-snRNA
potently enhanced release of IL-10 by PBMC under the
inﬂuence of PHA (Figure 8A). In contrast, PHA-induced
release of TNFa was signiﬁcantly suppressed by misplaced
U1-snRNA (Figure 8B), implying an anti-inﬂammatory
eﬀect mediated by U1-snRNA. In the absence of PHA,
IL-10 and TNFa remained undetectable in co-cultures
(Figure 8AB). Notably, when cultured without PBMC,
A549 cells exposed to misplaced U1-snRNA did not dis-
play secretion of IL-10, irrespective of the presence or
absence of PHA (data not shown).
Figure 5. Induction of IFN-b by U1-snRNA is dependent on the
ISRE-like PRDIII IFN-b promoter element. (A) For all experimental
conditions, A549 cells were transfected with 0.25mg of pGL3-IFNb
together with 0.1mg of pRL-TK (Promega) as described in the
‘Materials and Methods’ section, followed by a 20h period of rest.
Thereafter, cells were either kept as mock-transfected control or were
stimulated by additional transfection with U1-snRNA (0.1mg/ml) or
U1ctr (0.003mg/ml), respectively. Where indicated, cells were pre-incu-
bated (0.5h) with baﬁlomycin A1at 1mM. All cultures were adjusted to
a ﬁnal concentration of 0.1% DMSO (vehicle for baﬁlomycin A1)
throughout the experiment. After removal of liposomes (at 4h, see
‘Materials and Methods’ section) fresh baﬁlomycin A1 was added
where indicated. After an incubation period of 24h (total experiment:
24.5h), cells were harvested and luciferase reporter assays were per-
formed. Data are shown as means SD of fold-induction of IFNb
promoter activity compared to cells transfected with pGL3-IFNb but
without subsequent transfection with U1-snRNA for stimulation
(mock-transfection) (n=3);
  P<0.01 compared to cells transfected
with pGL3-IFNb but without subsequent transfection with U1-
snRNA for stimulation (mock-transfection),
##P<0.01 compared to
cells transfected with pGL3-IFNb and subsequently stimulated by
U1-snRNA transfection. (B) A549 cells were transfected with pGL3-
IFNb or pGL3-mutIFNb (mutated PRDIII region) at 1mg together
with 0.1mg of pRL-TK (Promega) as described in the ‘Materials and
Methods’ section, followed by a 20h period of rest. Thereafter, cells
were further kept as mock-transfected control or stimulated by addi-
tional transfection with U1-snRNA (0.1mg/ml) or U1ctr (0.003mg/ml),
respectively. After 24h, cells were harvested and luciferase reporter
assays were performed. Data are shown as means SD of fold-induc-
tion of IFNb promoter activity compared to cells transfected with the
same respective plasmid but without subsequent U1-snRNA transfec-
tion for stimulation (mock-transfection) (n=3);
  P<0.01 compared
to cells transfected with the same respective plasmid but without sub-
sequent U1-snRNA transfection for stimulation (mock-transfection),
##P<0.01 compared to cells transfected with pGL3-IFNb and subse-
quently transfected with U1-snRNA for stimulation.
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U2-snRNA, in similarity to U1-snRNA, consists of sev-
eral stretches of double-stranded RNA (50). Thus, for
proof of principle and further control, cellular response
to U2-snRNA transfection was investigated herein.
Notably, as detected by IRF3 activation, misplaced U2-
and U1-snRNA showed similar stimulatory activity
(Figure 9).
DISCUSSION
Using human lung A549 epithelial cells we demonstrate
for the ﬁrst time that endosomal delivery of U1-snRNA
mediates activation of the transcription factor IRF3, a
process associated with expression of IRF3-inducible
immunoregulatory parameters such as IFN-b, IDO and
IP-10/CXCL10. We also detected activation of A549
cells by misplaced U2-snRNA, an observation that is in
full agreement with sequence-independent sensing of
double-stranded RNA by TLR3 (51). In this sense, the
present data can be considered to be of unspeciﬁc
nature. However, current observations gain speciﬁcity by
the fact that ligand location particularly matters in the
context of TLR3 activation. Only U1-snRNA is supposed
to enrich in apoptotic bodies thus getting access to the
endosomal compartment in the course of eﬀerocytosis
whereas accumulation of U2-snRNA in apoptotic bodies
has never been reported (8–13). As already alluded to in
the ‘Materials and Methods’ section, we like to emphasize
that, on a cellular basis, the amount of U1-snRNA deliv-
ered per A549 cell (for transfection of 0.1mg/ml) is
approximately in the range of the endogenous U1-
snRNA pool. Mutational analysis of the IFN-b promoter
furthermore demonstrated that induction of the gene was
most likely mediated via IRF3. Several lines of evidence
indicate that TLR3 sensing double-stranded RNA likely
plays a crucial role for cellular activation in the context of
misplaced U1-snRNA. First, gene expression of IFN-b,
IDO and IP-10/CXCL10 was suppressed by pre-
incubation of cells with baﬁlomycin A1 suggesting that
an endosomal RNA sensing principle is key to activation
by U1-snRNA. Among those, TLR7/8 sensing single-
stranded RNAs are obvious candidates (52). However,
the TLR7/8 ligand resiquimod/R-848 failed to mimic
U1-snRNA action on A549 cells thus precluding a
major function of this receptor complex. A recent report
actually suggests a minor role for TLR7/8 in immunoac-
tivation by endogenous U1-snRNA. By using single-
stranded oligoribonucleotides the authors propose that
the three 20-O-methylated nucleosides present in U1-
snRNA, all located in single-stranded regions of the mole-
cule, impair activation of TLR7/8 by these sequences (53).
Two of those three nucleosides are located in a 6nt-long
Figure 6. Activation of STAT1 and STAT3 by U1-snRNA. (A and B) A549 cells were either kept as mock-transfected control or stimulated with U1-
snRNA (0.1mg/ml) or U1ctr (0.003mg/ml). After the indicated time periods, cellular content of pIRF3 (A and B), pSTAT1 (A) and pSTAT3 (B) was
determined by immunoblot analysis. For detection of pIRF3 and pSTAT1/3 on the same blot, blots were cut in half. For each experimental setup,
one representative of three independently performed experiments is shown. (C) A549 cells were either kept as mock-transfected control or stimulated
with U1-snRNA (0.1mg/ml) or U1ctr (0.003mg/ml). After 8h, cellular IL-18BP mRNA expression was assessed by quantitative realtime PCR
analysis. IL-18BP mRNA was normalized to that of GAPDH and is shown as fold induction compared with mock-stimulated control SD
(n=3);
  P<0.01 compared with mock-transfected control,
##P<0.01 compared to U1-snRNA stimulation. (D) A549 cells were either kept as
mock-stimulated control or were stimulated with U1-snRNA (0.1mg/ml). After 2h, nuclear content of p65 (upper panel) and pIRF3 (lower panel)
was determined by immunoblot analysis. For that purpose, blots were stripped and reprobed. As a positive control for p65 translocation and
negative control for IRF3 activation, mock-transfected cells were stimulated where indicated with the combination IL-1b/TNFa (each at 50ng/ml)
during the last hour of the 2h incubation period. One representative of four independently performed experiments is shown.
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that is in fact speciﬁcally cut oﬀ during apoptosis (54). The
remaining 20-O-methylated nucleoside in U1-snRNA is
a modiﬁed adenine located in the single-stranded loop B
of U1-snRNA (53,55). Collectively, these data imply
that at least two of the single-stranded segments of endo-
genous U1-snRNA are unable to activate TLR7/8 due to
nucleoside modiﬁcations. Cellular activation by U1-
snRNA was furthermore independent of 50-triphosphate
ends. Consequently, a role for cytosolic RIG-I in detecting
U1-snRNA appears unlikely (22). These observations
were complemented by lack of PKR activation as detected
by eIF2a phosphorylation (17) and thus altogether suggest
a prominent role for TLR3 in the cellular response
towards misplaced U1-snRNA. In this context, it is note-
worthy that TLR3 activation does not exclusively rely on
uninterrupted double-stranded RNA but apparently tol-
erates mismatches (56). Thus, according to their structures
(57) U1-snRNA [at stem-loop I and III: each 9bp, at
stem-loop II: 5 and 8bp, at stem-loop IV: 6bp (+3bp)]
and U2-snRNA [at stem-loop IV: 11bp, at stem-loop III:
8bp (+4bp)] show regions with double-stranded RNA
that may be able to fold into a three-dimensional ﬁt recog-
nized by TLR3. Recent analysis using synthetic RNA
duplexes revealed that 21bp are suﬃcient for activation
of TLR3 (58). Notably, this rigid model does not neces-
sarily mirror activation of TLR3 by endogenous RNA
populations.
Compared to IRF3, activation of STAT1/3 was delayed
and possibly related to production of intermediate factors
including IFN-b (59,60). In concurrence with activation of
STAT1 signaling, induction of anti-inﬂammatory IL-18BP
(48,49) was evident under the inﬂuence of U1-snRNA.
As a negative control, A549 cells were transfected with
human total RNA, a regime which in agreement with a
previous report (46) failed to show stimulatory capabil-
ities. As already alluded to, extensive nucleoside modiﬁca-
tions impair recognition of endogenous mammalian
Figure 7. Activation of DLD-1 cells by misplaced U1-snRNA. (A) DLD-1 cells were either kept as mock-transfected control or stimulated with
U1-snRNA (2.5mg/ml). Where indicated, cells were pre-incubated (0.5h) either with baﬁlomycin A1 (Baf, 1mM) or CHX (10mg/ml). All cultures
were adjusted to a ﬁnal concentration of 0.1% DMSO (vehicle for Baf and CHX) throughout the experiment. After an incubation period of 4h (total
experiment: 4.5h) cellular expression of pIRF3 was analyzed by immunoblot analysis. One representative of three independently performed experi-
ments is shown. (B) DLD-1 cells were either kept as mock-transfected control or were stimulated with U1-snRNA at 2.5mg/ml or U1ctr (0.075mg/ml)
for 6h or 12h. Thereafter, cells were harvested and IDO and IFN-b mRNA was assessed by RT-PCR analysis. One representative of three
independently performed experiments is shown. (C) DLD-1 cells were either kept as mock-transfected control or stimulated with U1-snRNA
(2.5mg/ml) for 6h or 12h. Thereafter, IDO protein expression was determined by immunoblot analysis. One representative of three independently
performed experiments is shown. (D) U1-snRNA was digested by treatment with benzonase as outlined in the ‘Materials and Methods’ section.
DLD-1 cells were either kept as mock-transfected control or stimulated with intact or digested U1-snRNA (each at 2.5mg/ml). After 20h, secretion of
IP-10 was determined by ELISA analysis. IP-10 levels (n=4) are expressed as means SD;
  P<0.01 compared to mock-transfected control.
##P<0.01 compared to U1-snRNA stimulation. (E) DLD-1 cells were either kept as mock-transfected control or were stimulated with either
U1-snRNA (2.5mg/ml) or U1ctr (0.075mg/ml). Where indicated, cells were pre-incubated (0.5h) with baﬁlomycin A1 (Baf, 1mM). All cultures
were adjusted to a ﬁnal concentration of 0.1% DMSO (vehicle for Baf) throughout the experiment. After an incubation period of 12h (total
experiment: 12.5h) secretion of IP-10 was determined by ELISA analysis. IP-10 levels (n=3) are expressed as means SD;
  P<0.01 compared to
mock-transfected control.
##P<0.01 compared to U1-snRNA stimulation.
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N6-methyladenosine and 2-thiouridine prevents activation
of TLR3 by endogenous RNA populations (46). Notably,
U1-snRNA neither contains N6-methyladenosine nor
2-thiouridine, the latter occurring uniquely in tRNA
(61,62). As mentioned before, 20-O-methylated nucleosides
have been associated with suppression of TLR7/8 activa-
tion by single-stranded RNA (46,53). Eﬀects of 20-O-
methylated nucleosides on TLR3 activation have, to the
best of our knowledge, not been speciﬁcally addressed.
However, since the three 20-O-methylated nucleosides of
endogenous U1-snRNA are located in single-stranded
regions of the molecule (at the very 50-end and in
loop B) (53,55) it appears highly unlikely that those are
able to interfere with TLR3 activation. Thus, endogenous
U1-snRNA is supposed to be capable of activating TLR3.
Immunoregulatory eﬀects of U1-snRNA were not
restricted to lung A549 cells but were also observed
in DLD-1 colon carcinoma cells. Activation of IRF3
as well expression of IDO, IFNb and IP-10 were ditto
hallmarks of activation in DLD-1 cells clearly demonstrat-
ing that this pathway also applies to cultured colon carci-
noma cells. However, it became apparent that, compared
to A549 cells, DLD-1 cells reacted somewhat less towards
transfection with U1-snRNA. It might be that uptake of
liposomes by DLD-1 cells is less eﬀective. Notably, TLR3
is detectable in DLD-1 cells (data not shown). However,
it might also be that TLR3 expression levels or its func-
tionality are diminished in DLD-1 cells, compared to
A549 cells. In fact, moderate/controlled responsiveness
towards TLR ligands might be key to epithelial biology
in the gut, an environment constantly exposed to myriads
of microbes and their debris. The basis for this interesting
diﬀerence in sensitivity between both cell types is currently
under investigation.
Since U1-snRNA enriches together with U1-RNP in
apoptotic bodies (8–13), the pathophysiological context
of the current study is in particular related to the immu-
nobiology of apoptosis. Intracellular degradation of
engulfed apoptotic cells/bodies is linked to the endosomal
pathway (63), a compartment supposed to harbor TLR3
expression (19,52). In agreement with previous data (47),
we demonstrate intracellular but not membrane expres-
sion of TLR3 in A549 cells. Endosomal delivery of
U1-snRNA by cationic liposomes was used to investigate
immunoregulation by U1-snRNA in relation to phagocy-
tosis. In fact, silent phagocytosis of apoptotic cells/bodies,
recently coined eﬀerocytosis, has been linked to immuno-
modulation, more speciﬁcally immunosuppression and
inhibition of inﬂammation (14,15,64,65). Interestingly,
among the IRF3-inducible parameters upregulated by
U1-snRNA were IDO and IFN-b. IDO is regarded a
most relevant mediator of immunosuppression (66).
Although the role of type I interferons in inﬂammation
is not discussed uniformly (67), anti-inﬂammatory/
therapeutic properties of IFNb have been identiﬁed in
the context of rheumatoid arthritis (68), inﬂammatory
Figure 8. Misplaced U1-snRNA mediates anti-inﬂammatory eﬀects as
detected in A549 cell/PBMC co-culture experiments. A549 cells were
either kept as mock-transfected control or stimulated with U1-snRNA
(0.1mg/ml) or U1ctr (0.003mg/ml), respectively. After removal of lipo-
somes at 4h, PBMC were seeded into transwell inserts (9 10
6 cells per
insert) and placed on top A549 cells for co-culturing as described in the
‘Materials and Methods’ section. Where indicated, PBMC were stimu-
lated with PHA (1mg/ml). After 72h, co-culture supernatants were
harvested and production of IL-10 (A) and TNF-a (B) was assessed
by ELISA analysis. Data are expressed as means SEM with n=4
(A) and 6 (B), respectively;
  P<0.01 compared to unstimulated
co-cultures with mock-transfected A549 cells,
#P<0.05 and
##P<0.01 compared to PHA-stimulated co-cultures with mock-
transfected A549 cells.
Figure 9. Activation of A549 cells by misplaced U2-snRNA. A549 cells
were either kept as mock-transfected control or were stimulated with
either U1-snRNA or U2-snRNA (both at 0.1mg/ml) or with U1ctr
or U2ctr (both at 0.003mg/ml). After 6h, cellular pIRF3 content
was determined by immunoblot analysis. One representative of three
independently performed experiments is shown.
Nucleic Acids Research, 2009 13bowel diseases (69,70) and multiple sclerosis where this
cytokine is approved for therapy (71). Notably, protection
by activation of TLR9 as seen in experimental colitis is
mediated by endogenous IFN-b (72). In that context, it
is moreover interesting to note that a therapeutic eﬀect
of TLR3 has been proposed for experimental colitis (73)
and asthma (74).
Upregulation of anti-inﬂammatory mediators such as
transforming growth factor (TGF)-ß (75) and IL-10 with
coinciding suppression of pro-inﬂammatory TNFa (76,77)
appears crucial for avoiding inﬂammation associated with
apoptosis. By using a transwell-cocultivation model
of A549 cells and PBMC, we demonstrate herein that
exposure of A549 cells to misplaced U1-snRNA redirects
PHA activation of PBMC thereby establishing an anti-
inﬂammatory cytokine milieu comparible with that pre-
viously observed in the context of apoptosis. Given the
key role of TNFa (78) and IL-10 (79) for immunoregula-
tion, present data suggest an overall anti-inﬂammatory
eﬀect of misplaced U1-snRNA concerning cytokine
production as detected in A549/PBMC cocultures.
Phagocytosis of apoptotic cells/bodies by epithelial cells
(26,27) not only serves to simply remove cell remnants but
beyond that appears to stabilize tissue homeostasis and
limit pathology by supporting an anti-inﬂammatory/
protective cytokine milieu (14,15,64,65). Current knowl-
edge on mechanisms of immunomodulation by eﬀerocy-
tosis is incomplete. By studying A549 lung epithelial
cells, we characterized misplaced U1-snRNA as a poten-
tial signal that may reprogram tissue behavior at host/
environment interfaces during epithelial eﬀerocytosis.
The latter being a crucial protective process that when
defective potentially favors a status of dysregulation
with accompanied inﬂammation as seen in patients with
cystic ﬁbrosis, asthma or chronic obstructive pulmonary
disease (80).
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